In Vitro and Ex Vivo Investigation of the Impact of Luminal Lipid Phases on Passive Permeability of Lipophilic Small Molecules Using PAMPA
article
OA: closed
CC0
⤵ 1 in-corpus citation
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
- Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug 2005
- Luminal Lipid Phases after Administration of a Triglyceride Solution of Danazol in the Fed State and Their Contribution to the Flux of Danazol Across Caco-2 Cell Monolayers 2012
Cited by (1)
References (38)
- Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug via openalex
- Luminal Lipid Phases after Administration of a Triglyceride Solution of Danazol in the Fed State and Their Contribution to the Flux of Danazol Across Caco-2 Cell Monolayers via openalex
- doi:10.1016/s0928-0987(97)00074-2 via openalex
- doi:10.1016/j.ijpharm.2004.01.014 via openalex
- W1181480766 via openalex
- W1594597698 via openalex
- W1981991919 via openalex
- doi:10.1007/s11095-008-9694-0 via openalex
- doi:10.1016/j.nano.2009.10.004 via openalex
- W2053390580 via openalex
- doi:10.1016/j.ejps.2013.04.002 via openalex
- doi:10.1080/10717540701606426 via openalex
- W2408643029 via openalex
- W4285719527 via openalex
- W6645900246 via openalex
- doi:10.1208/aapsj080101 via openalex
- doi:10.1016/0160-9327(85)90123-1 via openalex
- doi:10.1016/j.ijpharm.2006.01.029 via openalex
- doi:10.1517/17425255.1.2.325 via openalex
- doi:10.1002/jps.10290 via openalex
- doi:10.1201/9780824741969.axh via openalex
- doi:10.1021/js970332a via openalex
- doi:10.1172/jci108465 via openalex
- doi:10.1128/aac.42.6.1470 via openalex
- doi:10.1021/mp200286x via openalex
- doi:10.1016/0887-2333(96)00021-5 via openalex
- doi:10.1038/nrd2197 via openalex
- doi:10.1002/jps.21919 via openalex
- doi:10.1016/s0168-3659(01)00279-6 via openalex
- doi:10.1016/j.ijpharm.2008.04.034 via openalex
- doi:10.1021/mp200181v via openalex
- doi:10.1016/s0378-5173(02)00586-0 via openalex
- doi:10.1002/047145026x via openalex
- doi:10.4155/tde.10.40 via openalex
- doi:10.1038/nrd3187 via openalex
- doi:10.1080/03639040500465991 via openalex
- doi:10.1111/j.2042-7158.2010.01226.x via openalex
- doi:10.1007/s11095-008-9569-4 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-05-11T05:42:58.953575+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK